Investment analysts at Alliance Global Partners started coverage on shares of Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) in a research report issued on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Alliance Global Partners’ target price would indicate a potential upside of 229.34% from […]